Related Experiment Video
Updated: Nov 10, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Deranged Coagulation Profile Secondary to Cefazolin Use: Case Report
Jinghao Nicholas Ngiam1, Tze Sian Liong1, Sai Meng Tham2
1Department of Medicine, National University Health System, Singapore 119228, Singapore.
Abstract:
Cefazolin is a widely used first-generation cephalosporin. While generally well tolerated, several case reports have described severe coagulopathy induced by intravenous (IV) cefazolin. This was seen particularly in patients with impaired renal function, where antibiotic choice is limited and may require specific dose adjustments. Altered renal handling of antibiotics and their metabolites may potentiate toxicity and side effects. We report a case of a 72-year-old Chinese man who had been treated for methicillin-sensitive staphylococcus aureus (MSSA, coagulase-positive) infective endocarditis with cefazolin and, consequently, developed significantly elevated international normalised ratio (INR) while on therapy. This resolved within 48 h after cessation of cefazolin and administration of oral vitamin K. Malnourished patients with pre-existing or acute kidney injury may be at an increased risk of cefazolin-related coagulopathy.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Endocarditis IV: Nursing Management
Endocarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management

